Vanda Pharmaceuticals Inc.
VNDAStock
$5.45+22.90%52W
Market Cap$340.37M
P/E—
Div yield—
Beta0.61
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.96%
Price vs S&P 500 (4W)1.50%
VGM Score44.80
Market Capitalization$340.37M
Earnings Surprise History
Q1 26-0.82est. -0.70
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VNDAVanda Pharmaceuticals Inc. | C | C | D | $5.45 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Vanda Pharmaceuticals is a biopharmaceutical company developing therapies for neurology and psychiatry conditions with significant unmet medical needs. Its commercial portfolio includes HETLIOZ (for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome), Fanapt (schizophrenia), and PONVORY, with Fanapt generating the majority of revenue. The company operates primarily in the United States, with additional markets in Europe, Israel, and Canada, and maintains a pipeline of development-stage candidates.